Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Recommendation of “Hold” from Brokerages

Arvinas, Inc. (NASDAQ:ARVN) has been assigned an average rating of “Hold” from the twenty-two brokerages that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $16.7895.

ARVN has been the subject of a number of recent research reports. Barclays boosted their price objective on shares of Arvinas from $16.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Stephens upped their target price on Arvinas from $14.00 to $15.00 and gave the company an “overweight” rating in a report on Monday, November 10th. Wells Fargo & Company dropped their price target on Arvinas from $16.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Citigroup upgraded Arvinas from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $10.00 to $15.00 in a research report on Tuesday, January 6th. Finally, The Goldman Sachs Group restated a “sell” rating and set a $6.00 price objective (down from $8.00) on shares of Arvinas in a research note on Wednesday, October 15th.

Institutional Investors Weigh In On Arvinas

Several large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its position in Arvinas by 491.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after buying an additional 4,835 shares during the period. Canada Pension Plan Investment Board increased its holdings in shares of Arvinas by 109.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after purchasing an additional 3,500 shares during the period. State of Wyoming purchased a new stake in shares of Arvinas in the third quarter worth approximately $68,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Arvinas during the second quarter worth approximately $74,000. Finally, Virtus Investment Advisers LLC grew its position in Arvinas by 49.3% during the second quarter. Virtus Investment Advisers LLC now owns 12,422 shares of the company’s stock valued at $91,000 after purchasing an additional 4,104 shares in the last quarter. 95.19% of the stock is owned by institutional investors.

Arvinas Stock Performance

NASDAQ:ARVN opened at $13.38 on Friday. The firm’s fifty day simple moving average is $12.31 and its 200 day simple moving average is $9.85. Arvinas has a twelve month low of $5.90 and a twelve month high of $20.38. The firm has a market capitalization of $859.26 million, a price-to-earnings ratio of -16.52 and a beta of 1.89.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Wednesday, November 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.27. Arvinas had a negative return on equity of 9.77% and a negative net margin of 18.73%.The business had revenue of $41.90 million for the quarter, compared to analyst estimates of $29.36 million. During the same period in the previous year, the company earned ($0.68) earnings per share. The company’s revenue for the quarter was down 59.1% compared to the same quarter last year. On average, analysts predict that Arvinas will post -3.81 earnings per share for the current year.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.